Clin2
NCT06557213Possibly a fitNot yet recruiting

Gut bacteria in advanced liver cancer treatment

Liver Cancer

Part of Cancer, Digestive system clinical trials.

This study is for people with advanced liver cancer who are starting a new type of treatment that combines targeted therapy to block blood vessel growth and immune therapy to help your body fight the cancer. It looks at how gut bacteria might affect treatment response.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
18 years to 75 years
Study type
Observational

Who can take part

  • You are between 18 and 75 years old.
  • You have liver cancer that is moderately advanced or advanced (stage B or C) and cannot be removed by surgery.
  • You have not had any previous whole-body treatment for your liver cancer.
  • You plan to start treatment that combines targeted anti-angiogenic drugs with immune checkpoint inhibitors.
  • You have at least one measurable tumor on a scan, and you are in good general health (able to care for yourself).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06563934Not yet recruiting· Phase 2
Study of gut bacteria in liver cancer treated with TKI + immunotherapy

This trial tests how a combination of targeted therapy (TKI) and immunotherapy (ICI) affects the gut bacteria in people with advanced liver cancer that cannot be surgically removed. It aims to see if changes in the microbiome can help predict treatment response.

NCT06563947Not yet recruiting· Phase 2
Gut bacteria and liver cancer trial

This trial tests how gut bacteria affect liver cancer treatment. It is for people whose liver cancer worsened after certain targeted and immunotherapy drugs.

NCT07690683Not yet recruiting
Studying gut health in advanced liver cancer patients on immunotherapy

This study looks at how the gut microbiome affects treatment response in patients with advanced liver cancer who are receiving immunotherapy. It involves a colonoscopy to collect samples and may help improve future treatments.

Roma
NCT07186010Recruiting
Immune therapy biomarkers in advanced liver cancer

This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.

Seoul, Song-pa
NCT06551272Recruiting· Phase 2
Gut bacteria change to help immunotherapy for liver cancer

This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.

Bobigny
NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy

This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.

Pavia, Lombardy

Hear when a new Liver Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.